Bright Peak Therapeutics Announces $107 Million Series B Financing and Expanded Board of Directors

Bright Peak Therapeutics, a biotechnology company developing next-generation cytokine immunotherapies to treat cancer and autoimmune disease, today announced that it raised $107 million in a Series B financing.